The Pharma Data

MAY 5, 2022

Using donations, partnerships and collective action, Foundation S will focus on three critical areas: childhood cancer, the health of communities most vulnerable to the effects of climate change and pollution, and access to lifesaving medicines and vaccines. Vanina Laurent-Ledru will lead Foundation S.

Vaccine 52

Vaccine Treatment Hospitals International 52

The Pharma Data

OCTOBER 28, 2021

billion (up 10.1%) due to strong growth from Dupixent ® , Vaccines and CHC. Vaccines up16.5, with record daily deals driven by discerned flu vaccines and meningitis ballot recovery. We help illness with vaccines, give innovative treatments to fight pain and ease suffering. Q3 2021 sales grew double digit to €10.4

Vaccine 52

Vaccine Treatment Drugs 52

PerkinElmer

JANUARY 25, 2023

While the first steps were done using human-derived cell lines in 2D and 3D cultures, we now see the ascent of organoids and microphysiological systems built with iPSC or primary cells that mimic not only cellular behavior but also complex tissue behavior in response to treatment. With the expanding territory of I.

Science 52

Science Laboratories Immune Response Disease 52

NIH Director's Blog: Drug Development

MAY 15, 2018

In fact, the treatment that cured me would be of little use today. So, researchers have been searching the genome of Plasmodium falciparum , the most-lethal species of the malaria parasite, for potentially better targets for drug or vaccine development. References: [1] Overview of malaria treatment. World Health Organization.

Drug Development 52

Drug Development Drugs Disease Treatment 52

The Pharma Data

MAY 4, 2021

This donation furthers both Lilly and Direct Relief’s charitable goal of providing access to COVID-19 treatments to patients in need by providing these medicines free of charge to low- and lower-middle-income countries. Baricitinib has not been approved for the treatment of COVID-19, but has been authorized for emergency use by the FDA.

Therapies 52

Therapies Hospitals Treatment FDA Approval 52

The Pharma Data

APRIL 27, 2021

at CER driven by growth drivers Dupixent ® and Vaccines. Vaccines up 5.3%, driven by PPH franchise and demand for influenza vaccines in southern hemisphere. Vaccines delivered growth in its core segments. reflecting lower treatment compliance during the COVID-19 pandemic. Q1 2021 sales increase of 2.4% In the U.S.

Vaccine 52

Vaccine Production FDA Disease 52

The Pharma Data

OCTOBER 25, 2021

It further evolves Boehringer Ingelheim’s commitments and significantly increases the company’s donation to appreciatively impacting health, societal and environmental issues, in alignment with the United Nations 2030 Sustainable Development Goals.

Vaccine 52

Vaccine Hospitals Disease Treatment 52

The Pharma Data

MARCH 11, 2021

Sustainability forms an integral part of Bayer’s business strategy, growth plans and incentive systems, Baumann stressed, citing as an example the company’s decision to become carbon-neutral by 2030. Speeding up sales growth. Sales growth at Bayer is planned to regain momentum in 2021 and further accelerate in the years thereafter.

Science 52

Science Pharmaceuticals Licensing Licensing 52

The Pharma Data

JANUARY 9, 2021

• Anthrax Vaccines. Anthrax vaccine revenues are expected to be at a more normalized annual level and continue to primarily reflect procurement of AV7909 (Anthrax Vaccine Adsorbed, adjuvanted) under the Company’s existing contract with the Biomedical Advanced Research and Development Authority (BARDA).

Government 52

Government Vaccine Production Licensing 52

The Pharma Data

DECEMBER 18, 2020

COVAX now has agreements in place to access nearly two billion doses of several promising vaccine candidates, and laid the groundwork for further doses to be secured through contributions from donors. billion donor-funded doses of approved vaccines in 2021 to the 92 low- and middle-income economies eligible for the COVAX AMC.

Vaccine 52

Vaccine Government International Virus 52

The Pharma Data

FEBRUARY 8, 2021

Vaccines up 14.6%, driven by record demand for differentiated influenza vaccines and continued growth of PPH. to €36,041 million, driven by Dupixent ® (€3,534 million, up 73,9%) and Vaccines. We continue to work in parallel on our two COVID-19 vaccine candidates, with clinical trials starting in the coming weeks.

Vaccine 52

Vaccine Production FDA Therapies 52

The Pharma Data

FEBRUARY 4, 2021

Vaccines up 14.6%, driven by record demand for differentiated influenza vaccines and continued growth of PPH. to €36,041 million, driven by Dupixent ® (€3,534 million, up 73,9%) and Vaccines. We continue to work in parallel on our two COVID-19 vaccine candidates, with clinical trials starting in the coming weeks.

Vaccine 52

Vaccine Production FDA Therapies 52

The Pharma Data

SEPTEMBER 15, 2020

Next-generation biomarker cytology test supports World Health Organization’s goal to eliminate cervical cancer, which is nearly 100 percent preventable with proper screening, vaccination and treatment. The World Health Organization has set goals for countries to take action to eliminate cervical cancer by 2030.

FDA Approval 52

FDA Approval FDA Laboratories Disease 52